Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Guoming Shi
Observed name:
GUO-MING SHI
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Jinshan Hospital of Fudan University,
Zhongshan Hospital
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Jinshan Hospital of Fudan University,
Zhongshan Hospital
ORCID:
0000-0003-3817-9117
Observed ORCID:
0000-0003-3817-9117
OpenAlex ID:
A5083024618
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study
2025
·
Guoming Shi
, Xiaoyong Huang
, et al.
·
The Lancet Oncology
·
33
Adjuvant lenvatinib after radical resection in patients with hepatocellular carcinoma (HCC): Preliminary analysis of a prospective, multi-center, single-arm study.
2022
·
Jian Zhou
, Hui-Chuan Sun
, et al.
·
Journal of Clinical Oncology
·
14
Clinical outcomes from a phase I clinical trial of a novel oncolytic virus VG161 in patients with hepatocellular carcinoma (HCC) refractory after 2 prior lines of therapy including checkpoint inhibitors (CPI).
2024
·
Yinan Shen
, Xingmei Liang
, et al.
·
Journal of Clinical Oncology
·
11
PDF
Prognostic significance of nuclear RNA export factor 3 in hepatocellular carcinoma
2014
·
JIA-HAO JIANG
, QIANG GAO
, et al.
·
Oncology Letters
·
9
PDF
Two stage, multi-center trial of cadonilimab and LM-302 for patients with CLDN18.2+ biliary tract cancer (BTC) that failed chemotherapy and PD-(L)1 antibody (ZSAB-Calm).
2024
·
Jia Fan
, Jian Zhou
, et al.
·
Journal of Clinical Oncology
·
7
The Evolving Role of Artificial Intelligence in Medical Genetics: Advancing Healthcare, Research, and Biosafety Management
2025
·
Ying-Cheng Wu
, Nan Tuo
, et al.
·
Genes
·
6
PDF
Pemigatinib in Chinese patients with advanced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 fusion or rearrangement: Updated data from an open-label, single-arm, multicenter phase II study (CIBI375A201 study).
2022
·
Guoming Shi
, Xiaoyong Huang
, et al.
·
Journal of Clinical Oncology
·
6
Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS -Mutant Cholangiocarcinoma
2026
·
Jian Lin
, Chen Sang
, et al.
·
Cancer Discovery
·
5
Graft PD-L1 as a predictive marker for rejection in PD-1 inhibitor therapy for recurrent liver tumors after transplant: A prospective pilot trial
2025
·
Yifeng He
, Xiaowu Huang
, et al.
·
Liver Transplantation
·
5
Trends and cross-country inequalities in the global, regional, and national burden of gallbladder and biliary tract cancer from 1990 to 2021, along with the predictions for 2035
2025
·
Wen Bao
, Lichun Qiao
, et al.
·
Cancer Epidemiology
·
5
694 An open-label phase I dose-escalation clinical trial to evaluate the safety, tolerability, pharmacokinetic profile and preliminary efficacy of VG161 in patients with advanced primary liver cancer
2022
·
Yinan Shen
, Guoming Shi
, et al.
·
Journal for ImmunoTherapy of Cancer
·
5
PDF
A single-arm, multi-center phase II study of tislelizumab combined with lenvatinib and GEMOX as conversion therapy in potentially resectable locally advanced biliary tract cancer (ZSAB-TransGOLP): A primary analysis.
2024
·
Jia Fan
, Jian Zhou
, et al.
·
Journal of Clinical Oncology
·
2
PDF
Abstract CT159: JS207, a bispecific antibody targeting PD-1 and VEGF-A, combined with JS007 (anti-CTLA4), for patients with advanced hepatocellular carcinoma in a randomized, multicenter, Phase II study
2026
·
Jian Zhou
, Guoming Shi
, et al.
·
Cancer Research
·
1
Sequential hepatic artery infusion chemotherapy and transarterial chemoembolization combined with anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors and immune checkpoint inhibitors (quadruple therapy) as first-line therapy for advanced hepatocellular carcinoma: A single-center retrospective cohort study.
2025
·
Xiao-Yong Huang
, Wei Du
, et al.
·
Journal of Clinical Oncology
·
1
Abstract CT153: Pemigatinib in Chinese patients with advanced/metastatic or surgically unresectable cholangiocarcinoma Including FGFR2 fusion or rearrangement: Updated overall survival from an open-label, single-arm, multicenter Phase II study
2023
·
Guoming Shi
, Xiaoyong Huang
, et al.
·
Cancer Research
·
1
cfDNA-derived gene signatures as surrogate for microvascular invasion in HCC
2026
·
Ruijie Gong
, Linchen Wang
, et al.
·
JHEP Reports
PDF
Abstract LB272: A neoantigen mRNA vaccine generates antitumor immunity in a murine model of intrahepatic cholangiocarcinoma
2026
·
Mantang Qiu
, Jiacheng Lu
, et al.
·
Cancer Research
Future of ALPPS
2025
·
Jian Zhou
, Zheng Wang
, et al.
·
Springer eBooks
PDF
Show more works
View as search
Works count:
18
Citation count:
109
H-index:
6
I10-index:
3
Year
Topic
Type